Margot K Davis is an expert in Cardiology at University of British Columbia (Canada). As of October 2026, ScienceLeadR ranks Margot K Davis in the top 1% of experts in Canada for Transthyretin Amyloid Cardiomyopathy. Margot K Davis has authored 113 publications, the most recent in 2026, and is an investigator in 4 clinical trials. SLR score: 459 (community average: 125). How the SLR is computed.

LeadR Profile

Margot K Davis University of British Columbia Canada
459 ScienceLeadR Reputation 459
Network Map

Cardiology

Subspecialties: Biochemistry - Urology - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2011 - 2026

Source: PubMed

University of British Columbia

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 113

Citations

Citations: 8 088 1st author: 19 Last author: 21 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Closing the Gaps in Heart Failure Care: A Call for a National Strategy in Canada.
PMID 42861294 — research design, heart failure, heart, diagnosis, therapeutics
CJC Open20260
Clinical and Echocardiographic Characteristics of Neuroendocrine Tumours and Carcinoid Heart Disease: Insights from a Contemporary Canadian Cohort.
PMID 42756817 — heart valve diseases, mortality, heart diseases, heart, neoplasms, echocardiography, diagnosis, carcinoid heart disease, carcinoid tumor
CJC Open20260
Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial.
PMID 42742182 — genes, molecular biology, prealbumin, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy
Nat Med Top journal20260
Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis.
PMID 42693367 — mortality, prealbumin, sex characteristics, sex, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis, sex differences
Cardiol Ther20260
Long-term effects of acoramidis on mortality in variant transthyretin amyloid cardiomyopathy, including p.Val142Ile: findings from the open-label extension of ATTRibute-CM.
PMID 42669031 — mortality, heart failure, prealbumin, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy
Eur J Heart Fail20260

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 3
N/A 1

By status:

Completed 3
Active not recruiting 1

By type:

Interventional 4

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 4

Main Topics

LeadR Networks

Main global connection map